Dr. Howard Verrico reports

SIRONA BIOCHEM RECEIVES POSITIVE CLINICAL RESULTS OF ITS SKIN LIGHTENING COMPOUND TFC-1067 FROM CHINA

Sirona Biochem Corp. has released results of a clinical trial performed in the People's Republic of China using Sirona's novel skin lightening agent, TFC-1067. Sirona's TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.

A major distributor of cosmetics materials in China arranged clinical testing of TFC-1067 to be done by a select group of its key cosmetic customers. The formulation used in the studies was the same as that used in Sirona's first clinical trial in the United States by Dr. Zoe Draelos. The clinical trial design protocols and the testing was conducted independently of Sirona by the cosmetic companies. The studies were conducted in Guangzhou, China.

A total of 60 participants were involved in the studies conducted over several sites. All participants applied the formulation with TFC-1067 twice daily to the face. Each study duration was four weeks. During the four weeks 90 per cent of participant reported a brightening effect with TFC-1067. Sirona is informed by the distributor that a second set of trials with Sirona's improved, next-generation, formulation is under way.

Dr. Geraldine Deliencourt-Godefroy, chief scientific officer of Sirona Biochem, stated: "These are excellent clinical results. Based on the outcome from our first clinical trial, we are pleased to see such results for the short four-week duration of the testing. This positive testing result on Asian skin with the observed lightening effect supports the clinical effect of TFC-1067 over different skin types. A longer trial is required to assess dyschromia which was assessed in Sirona's U.S.-based clinical trial. Sirona will await feedback on the further testing currently ongoing in China with our new formulation."

"No clinical safety issues were reported with TFC-1067 during the trial. TFC-1067 has shown a lightening effect over a short clinical trial on Asian skin types," reported Dr. Howard Verrico, chief executive officer of Sirona Biochem. "Although we prefer to conduct trials with a double blinded protocol using a comparative compound and a longer trial duration as we arranged in the USA, it was important to have these cosmetic companies perform their own clinical testing independently and be confident of the results. TFC-1067 continues to deliver excellent clinical results as anticipated by our preclinical assays. A strong commercial interest in TFC-1067 is already reported by the distributor based on current results."

"Sirona's team remains dedicated to work toward entering this market with a safe and effective alternative to current options. We are moving forward on building our relationship with the Chinese distributor with more positive news anticipated near term," Dr. Verrico concluded.

The global skin lightening market is estimated to grow to $31.2-billion (U.S.) by 2024. Asia makes up the largest and fastest-growing segment of the market. A World Health Organization survey reported that nearly 40 per cent of women polled in China said they regularly used whitening products many of which are toxic.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules, with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

We seek Safe Harbor.